TY - JOUR AU - Ojha, Rajeev AU - Karn, Ragesh PY - 2019/06/20 Y2 - 2024/03/28 TI - Clinical Outcome of Intravenous Immunoglobulin in the treatment of Guillain Barre Syndrome in a Nepalese Tertiary Centre JF - Nepalese Medical Journal JA - Nep. Med. J. VL - 2 IS - 1 SE - Original Articles DO - 10.3126/nmj.v2i1.24000 UR - https://www.nepjol.info/index.php/nmj/article/view/24000 SP - 133-137 AB - <p><strong>Introduction:</strong> Intravenous Immunoglobulin is an approved therapy for Guillain Barre Syndrome.&nbsp;Our objective is to understand the management and outcome in Guillain Barre Syndrome patients&nbsp;treated with Immunoglobulin.<br><strong>Materials and Methods:</strong> All consecutive patients were retrospectively evaluated in the study were&nbsp;of age ≥16 years and were being admitted in the department of Neurology of Tribhuvan University&nbsp;Teaching Hospital, Kathmandu, Nepal from 2016 March to 2017 February.<br><strong>Results:</strong> A total of 46 patients were included, mean age= 36.5±16.2 years, range = 16years to 80&nbsp;years. Thirty-two patients (70%) were axonal variant, acute motor axonal neuropathy is more&nbsp;common (18 patients). Intravenous immunoglobulin was used in 23 patients (50%), 17 of them&nbsp;were axonal variant and 6 were demyelinating. Guillain Barre Syndrome patients with bilateral&nbsp;facial weakness (70% vs 30%; p&lt;0.05) were likely to receive immunoglobulin therapy. Patients&nbsp;with immunoglobulin were found to have higher ODSS at Nadir (9.3±1.8 vs 6.9±1.9; p &lt;0.001)&nbsp;and discharge than patients without immunoglobulin treatment (6.2±1.7 vs 5.0±1.6; p=0.001). At&nbsp;Nadir, Patients with immunoglobulin were found to have higher Guillain Barre Syndrome disability&nbsp;score (4.1±0.7 vs 3.2±0.9; p&lt;0.095). In immunoglobulin group, Axonal variants were found to have<br>higher ODSS score (9.6±1.9 vs 8.2±0.9, p=0.027) and Guillain Barre Syndrome disability score&nbsp;(4.2±0.7 vs 3.5±0.5; p=0.019) at nadir than demyelinating group.<br><strong>Conclusions:</strong> Intravenous Immunoglobulin is easier to administer and is safe with fewer adverse&nbsp;effects. Although expensive, it is an effective treatment option in a resource-limited center. Axonal&nbsp;variants are clinically severe and likely to be need of Intravenous Immunoglobulin therapy.</p> ER -